Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://link.springer.com/article/10.1007/s11912-012-0249-5, but it redirected us to https://link.springer.com/article/10.1007/s11912-012-0249-5. The analysis below is for the second page.

Title[redir]:
Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies | Current Oncology Reports
Description:
The identification of somatic driver mutations in human samples has allowed for the development of a molecular classification for melanoma. Recent breakthroughs in the treatment of metastatic melanoma have arisen as a result of these significant new insights into the molecular biology of the disease, particularly the development of inhibitors of activating BRAFV600E mutations. In this article the roles of several mutations known to be involved in the malignant transformation of melanocytes are reviewed including BRAF, PTEN, NRAS, ckit, and p16 as well as some of the emerging mutations in cutaneous and uveal melanoma. The bench to bedside collaborations that resulted in these discoveries are summarized, and potential therapeutic strategies to target driver mutations in specific patient subsets are discussed.

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 80,479,999 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don't see any clear sign of profit-making.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Doi.org might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

google, scholar, melanoma, article, cancer, mutations, braf, res, cell, nras, clin, metastatic, mutation, human, pten, uveal, malignant, therapeutic, nature, oncol, cutaneous, dermatol, melanomas, med, patients, invest, somatic, target, gene, primary, phase, pubmed, kluger, molecular, ckit, potential, access, survival, tumor, trial, nat, clinical, frequent, imatinib, privacy, cookies, content, studies, mehnert, inhibitor,

Topics {✒️}

stem cell factor/c-kit proto-oncogene c-kit expression high-dose imatinib mesylate month download article/chapter c-kit-dependent growth kit kinase-domain mutation oncogene-defined taxonomy leads c-kit receptor article  google scholar pten-akt3 signaling cascade activated c-met placebo-controlled study nras-mutated human melanomas privacy choices/manage cookies somatic driver mutations full article pdf related subjects comparative histologic features activated n-rasq61k ap-2 transcription factor gene encoding brca1 target driver mutations genomics references papers lentigo maligna subtypes melanoma cell lines identify inactivating mutations genes chromosomes cancer natl cancer inst mmac1/pten gene independent prognostic factor neural system tumors mutations occur early potential therapeutic strategies tumor cell proliferation gene expression studies european economic area specific patient subsets ink4a-deficient background differentially impact prognosis bassett rl jr pi3k effector pathways ink4a/arf interactions genotype-phenotype relationships asco education booklet pten deficiency cooperates potential therapeutic response n-ras upregulation human lung cancer multikinase inhibitor sorafenib potential therapeutic target

Questions {❓}

  • Chemotherapy and biologic therapies for melanoma: do they work?
  • C-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies
         description:The identification of somatic driver mutations in human samples has allowed for the development of a molecular classification for melanoma. Recent breakthroughs in the treatment of metastatic melanoma have arisen as a result of these significant new insights into the molecular biology of the disease, particularly the development of inhibitors of activating BRAFV600E mutations. In this article the roles of several mutations known to be involved in the malignant transformation of melanocytes are reviewed including BRAF, PTEN, NRAS, ckit, and p16 as well as some of the emerging mutations in cutaneous and uveal melanoma. The bench to bedside collaborations that resulted in these discoveries are summarized, and potential therapeutic strategies to target driver mutations in specific patient subsets are discussed.
         datePublished:2012-06-22T00:00:00Z
         dateModified:2012-06-22T00:00:00Z
         pageStart:449
         pageEnd:457
         sameAs:https://doi.org/10.1007/s11912-012-0249-5
         keywords:
            Melanoma
            Somatic mutations
            Drug targeting
            Oncology
         image:
         isPartOf:
            name:Current Oncology Reports
            issn:
               1534-6269
               1523-3790
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Current Science Inc.
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Janice M. Mehnert
               affiliation:
                     name:The Cancer Institute of New Jersey
                     address:
                        name:The Cancer Institute of New Jersey, New Brunswick, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Harriet M. Kluger
               affiliation:
                     name:Yale Cancer Center
                     address:
                        name:Yale Cancer Center, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies
      description:The identification of somatic driver mutations in human samples has allowed for the development of a molecular classification for melanoma. Recent breakthroughs in the treatment of metastatic melanoma have arisen as a result of these significant new insights into the molecular biology of the disease, particularly the development of inhibitors of activating BRAFV600E mutations. In this article the roles of several mutations known to be involved in the malignant transformation of melanocytes are reviewed including BRAF, PTEN, NRAS, ckit, and p16 as well as some of the emerging mutations in cutaneous and uveal melanoma. The bench to bedside collaborations that resulted in these discoveries are summarized, and potential therapeutic strategies to target driver mutations in specific patient subsets are discussed.
      datePublished:2012-06-22T00:00:00Z
      dateModified:2012-06-22T00:00:00Z
      pageStart:449
      pageEnd:457
      sameAs:https://doi.org/10.1007/s11912-012-0249-5
      keywords:
         Melanoma
         Somatic mutations
         Drug targeting
         Oncology
      image:
      isPartOf:
         name:Current Oncology Reports
         issn:
            1534-6269
            1523-3790
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Current Science Inc.
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Janice M. Mehnert
            affiliation:
                  name:The Cancer Institute of New Jersey
                  address:
                     name:The Cancer Institute of New Jersey, New Brunswick, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Harriet M. Kluger
            affiliation:
                  name:Yale Cancer Center
                  address:
                     name:Yale Cancer Center, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Oncology Reports
      issn:
         1534-6269
         1523-3790
      volumeNumber:14
Organization:
      name:Current Science Inc.
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Cancer Institute of New Jersey
      address:
         name:The Cancer Institute of New Jersey, New Brunswick, USA
         type:PostalAddress
      name:Yale Cancer Center
      address:
         name:Yale Cancer Center, New Haven, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Janice M. Mehnert
      affiliation:
            name:The Cancer Institute of New Jersey
            address:
               name:The Cancer Institute of New Jersey, New Brunswick, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Harriet M. Kluger
      affiliation:
            name:Yale Cancer Center
            address:
               name:Yale Cancer Center, New Haven, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:The Cancer Institute of New Jersey, New Brunswick, USA
      name:Yale Cancer Center, New Haven, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(174)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

3.96s.